Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

The new anti-tumor weapon PDX model helps the development of new immune cancer drugs

2020-04-30
|
Page View:

On April 22, 2020, Dr. Chunlin Chen, founder and CEO of Medicilon, delivered a special lecture entitled “Application of Translational Medicine (PDX Model) in the Research and Development of New Immune Cancer Drugs”  Run Run Shaw Hospital affiliated to Medical College of Zhejiang University . The medical staff and medical students of the company shared the construction of the PDX mouse model in the context of tumor treatment and how it promotes the development of individualized tumor treatment and how to serve Chinese cancer patients.

Dr. Chunlin Chen, founder and CEO of Medicilon
Dr. Chunlin Chen, founder and CEO of Medicilon

Medicilon now has nearly ten PDX tumor efficacy models such as gastric cancer and colon cancer, and is committed to accurate drug efficacy evaluation. In the future, the company will focus on improving the highly humanized mouse disease model biobank, providing modern precision medicine with animal models that are highly compatible with human disease characteristics, and developing the most ideal humanized mouse model.
In recent years, with the advancement of high-throughput sequencing technology and targeted therapies, tumor diseases have made breakthrough progress in basic research, translational medicine and clinical research, but many traditional and new therapies for tumors have not brought patients Better prognosis, the failure rate of clinical translational research makes the innovation and development of anti-tumor drugs very limited. The human tumor tissue xenograft model (PDX) is a tumor model established on immunodeficient mice directly from tumor tissues of tumor patients. Because it maintains the tissue structure, morphology, and molecular biological characteristics of clinical tumor tissues, it is more and more widely used in preclinical drug efficacy evaluation and identification of potential biomarkers. It has become a major boost in tumor treatment and has become Hot spots of industry research.

About Medicilon

Medicilon (stock code: 688202) is a drug development outsourcing service company (CRO). Founded on February 2, 2004, the company has gone through 16 years and established a company in Shanghai that integrates compound synthesis, compound activity screening, structural biology, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicological evaluation, and formulation research A comprehensive technical service platform that conforms to international standards and is integrated with new drug registration, and has been recognized by the international drug management department. Medicipua’s animal laboratory facilities have obtained AAALAC (International Association for Animal Evaluation and Certification) certification and National Medical Products Administration NMPA GLP certification, and have reached the US Food and Drug Administration GLP standard.

Medicilon has a rich of experience in global cooperation. Since 2015, Medicilon has served more than 500 active customers worldwide. It has served many global pharmaceutical companies such as Takeda Pharmaceuticals, Johnson & Johnson Pharmaceuticals, GlaxoSmithKline, Roche Pharmaceuticals, etc. R&D outsourcing services are provided by well-known domestic and foreign customers such as Swiss Medicine, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, and Zhongsheng Pharmaceutical.

Return
Relevant newsRelevant news